Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 539-542

  Bonnefoi, H R ^a   Smith, I E ^a,e   Dowsett, M ^a   Trunet, P F ^b   Houston, S J ^c   Da Luz, R J ^c   Rubens, R D ^c   Coombes, R C ^d   Powles, T J ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CIBA GEIGY LTD   (Switzerland)

^c GUY S HOSPITAL   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitor; Breast cancer; Fadrozole

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; ESTRONE SULFATE; FADROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ENDOCRINE FUNCTION; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STATISTICAL ANALYSIS; TREATMENT FAILURE;

EID: 0030041360     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.93     Document Type: Article

References (26)

1. BERETTA KR, HOEFFKEN K, KVINNSLAND S, TRUNET P, CHAUDRI HA, BHATNAGAR AS, GOLDHIRSCH A AND CAVALLI F. (1990). CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer - a phase I study. Ann. Oncol., 1, 421-426.
2. DOWSETT M. (1990). Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J. Steroid Biochem., 37, 1037-1041.
3. DOWSETT M, STEIN RC, MEHTA A AND COOMBES RC. (1990). Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin. Endocrinol., 32, 623-634.
4. DOWSETT M, SMITHERS D, MOORE J, TRUNET P, COOMBES RC, POWLES TJ, RUBENS R AND SMITH IE. (1994). Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur. J. Cancer, 30A, 1453-1458.
5. GEORGE SL. (1988). The required size and length of a phase III clinical trial. In Cancer Clinical Trials - Methods and Practice, Buyse ME, Staquet MJ and Sylvester JR. (eds) Chapter 18. Oxford Medical Publication: Oxford.
6. GOSS PE AND GWYN KMEH. (1994). Current persectives on aromatase inhibitors in breast cancer. J. Clin. Oncol., 12, 2460-2470.
7. HAYWARD JL, RUBENS RD AND CARBONE PP. (1977). Assessment of response to therapy in advanced breast cancer. Br. J. Cancer., 35, 292-298.
8. HOEFFKEN K, CHACON R, DOMBERNOWSKY P, GOSS P, WILLEMSE P, ENGAN T, BONTE J, TUBIANA-HULIN M, LOPEZ-LOPEZ JJ, ELOMAA I, CHAUDRI H AND TRUNET P. (1992). Fadrozole hydrochloride (CGS 16949A), a double-blind dose finding study in postmenopausal women with advanced breast cancer. Ann. Oncol., 3, (suppl.5), 76.
9. LIPTON A, SANTNER SJ, SANTEN RJ, HARVEY HA, FEIL PD, WHITE-HERSHEY D, BARTHOLOMEW MJ AND ANTLE CE. (1987). Aromatase activity in primary and metastatic human breast cancer. Cancer, 59, 779-782.
10. LIPTON A, HARVEY HA, DEMERS LM, HANAGAN JR, MULAGHA MT, KOCHAK GM, FIZSIMMONS S, SANDERS SI, SANTEN RJ. (1990). A phase I trial of CGS 16949A - a new aromatase inhibitor. Cancer, 65, 1279-1285.
11. LONGCOPE C. (1982). Methods and results of aromatization studies in vivo. Cancer Res., 42, (suppl.), 3307-3311.
12. LONGCOPE C, PRATT JH, SCHNEIDER SH AND FINEBERG SE. (1978). Aromatization of androgens by muscle and adipose tissue in vivo. J. Clin. Endocrinol. Metab., 46, 146-152.
13. MACNEILL FA, JONES AL, JACOBS S, LONNING PE, POWLES TJ AND DOWSETT M. (1992). The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br. J. Cancer, 66, 692-697.
14. MILLER WR. (1989). Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat. Rev., 16, 83-93.
15. MURRAY R AND PITT P. (1985). Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur. J. Cancer Clin. Oncol., 21, 19-22.
16. POWLES TJ. (1983). The role of aromatase inhibitors in breast cancer. Semin. Oncol., 10, (suppl.4), 20-24.
17. RAATS JI, FALKSON G AND FALKSON HC. (1992). A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J. Clin. Oncol., 10, 111-116.
18. SANTEN RJ, LIPTON A AND KENDALL J. (1974). Successful medical adrenalectomy with aminoglutethimide. Role of altered drug metabolism. JAMA, 261, 1661-1665.
19. SANTEN RJ, SANTNER S, DAVIS B, VELDHUIS J, SAMOJLIK E AND RUBY F. (1978). Aminoglutethimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. J. Clin. Metab., 47, 1257-1265.
20. SANTEN RJ, DEMERS LM, ADLERCREUTZ H, HARVEY H, SANTNER S, SANDERS S AND LIPTON A. (1989). Inhibition of aromatase with CGS 16949A in postmenopausal women. J. Clin. Endocrinol. Metab., 68, 99-106.
21. STEELE RE, MELLOR LB, SAWYER WK, WASVARY JM AND BROWNE LJ. (1987). In vitro and in vivo studies demonstrating potent and selective oestrogen inhibition with the non-steroidal aromatase inhibitor CGS 16949A. Steroids, 50, 147-161.
22. STEIN RC, DOWSETT M, DAVENPORT J, HEDLEY A, FORD HT, GAZET J-C AND COOMBES RC. (1990). Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res., 50, 1381-1384.
23. STUART-HARRIS R AND SMITH IE. (1984a). Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet, 2, 604-607.
24. STUART-HARRIS RC AND SMITH IE. (1984b). Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat. Rev., 11, 189-204.
25. THÜRLIMANN B, BERETTA K, BACCHI M, GOLDHIRSCH A, JUNGI WF, CASTIGLIONE M, CAVALLI F, SENN HJ AND FEY M. (1995). First line fadrozole HCl (CGS 16949A) versus tamoxifen (TAM) in advanced breast cancer: prospective randomised study SAKK 20/88. ASCO Abstracts, 90, 98.
26. WHO. (1979). WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. World Health Organization: Geneva.